Search
Fluticasone
go.drugbank.com/drugs/DB13867ApprovedInvestigationalWithdrawnFluticasone is a synthetic glucocorticoid available as 2 esters, DB08906 and DB00588 [FDA Label]. These drugs are available as inhalers, nasal, sprays, and topical treatments for various inflammatory indications [FDA Label]. DB00588 was ...
Degarelix
go.drugbank.com/drugs/DB06699ApprovedInvestigationalFDA approved on December 24, 2008. … Degarelix is a synthetic peptide derivative drug which binds to gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland and blocks interaction with GnRH.
Grapiprant
go.drugbank.com/drugs/DB12836InvestigationalVet approved[L4766] Grapiprant has been approved in March 2016 by the FDA's Center for Veterinary Medicine as a non-cyclooxygenase inhibiting NSAID for veterinary use.[A39836] … [A39816] This class of drugs was defined in 2013 by the World Health Organization.
Bilastine
go.drugbank.com/drugs/DB11591ApprovedBilastine is a novel new-generation antihistamine that is highly selective for the H1 histamine receptor, has a rapid onset and prolonged duration of action.
Categories: Histamine H1 Antagonists, Non-SedatingZomepirac
go.drugbank.com/drugs/DB04828ApprovedWithdrawnZomepirac, formerly marketed as Zomax tablets, was associated with fatal and near-fatal anaphylactoid reactions. The manufacturer voluntarily removed Zomax tablets from the Canadian, US, and UK markets in March 1983.
Categories: Analgesics, Non-Narcotic, Non COX-2 selective NSAIDSPhensuximide
go.drugbank.com/drugs/DB00832ApprovedThe frequency of attacks is reduced by depression of nerve transmission in the motor cortex.
Oxilofrine
go.drugbank.com/drugs/DB11610ApprovedIt is currently marketed in Canada by Valeant under the tradename Cophylac.
Streptokinase
go.drugbank.com/drugs/DB00086ApprovedInvestigationalWithdrawnStreptokinase, is a sterile, purified preparation of a bacterial protein elaborated by group C (beta) -hemolytic streptococci.
Drotrecogin alfa
go.drugbank.com/drugs/DB00055ApprovedWithdrawnDrotrecogin alfa was withdrawn from the market after a major study indicated that it was not effective in improving outcomes in patients with sepsis. … Drotrecogin alfa is activated human protein C that is synthesized by recombinant DNA technology.
Copper oxodotreotide Cu-64
go.drugbank.com/drugs/DB15873Approved[A220348] Copper Cu 64 dotatate has a longer half-life and can be produced once a day as opposed to several times a day, and lower positron energy lending to improved spatial resolution. … [A220348] Further studies should be performed to compare the two tracers.